Analysts at Credit Suisse have upgraded this pharmaceutical company’s shares to an outperform rating from neutral with an increased price target of $1.00. The broker has made the move after assessing the market opportunity for two news products Mayne Pharma plans to release this year. Furthermore, the broker has suggested that investors view any earnings season share price weakness as a buying opportunity.
MYX Price at posting:
88.8¢ Sentiment: Hold Disclosure: Held
